打开APP

Takeda和Zinfandel针对阿尔兹海默症生物标记物研究进展顺利

  1. Takeda
  2. Zinfandel
  3. 生物标记物

来源:生物谷 2013-07-26 15:47

2013年7月25日讯 /生物谷BIOON/ --Takeda和Zinfandel公司透露他们联合研发的关于阿尔兹海默症的生物标记物TOMM40研究进展顺利,在早期测试中获得了理想的结果。在第三期实验中,两公司将继续合作进行更深入研究。研究人员表示,该生物标记物目前能够有70%-80%的概率正确预测阿尔兹海默症的病情发展。这项成果一旦成功将对阿尔兹海默症的早期预防及治疗提供很大帮助。

2013年7月25日讯 /生物谷BIOON/ --Takeda和Zinfandel公司透露他们联合研发的关于阿尔兹海默症的生物标记物TOMM40研究进展顺利,在早期测试中获得了理想的结果。在第三期实验中,两公司将继续合作进行更深入研究。研究人员表示,该生物标记物目前能够有70%-80%的概率正确预测阿尔兹海默症的病情发展。这项成果一旦成功将对阿尔兹海默症的早期预防及治疗提供很大帮助。(生物谷Bioon.com)

详细英文报道:

Takeda Pharmaceuticals and Zinfandel Pharmaceuticals say their new genetics-based Alzheimer's biomarker risk assignment algorithm generated promising results in early testing. A Phase III trial will advance the concept further, continuing a partnership between the companies formed more than two years ago.

Michael Lutz, a senior research scientist of Duke University School of Medicine's Department of Neurology, is the principal investigator in the project and he presented results at the recent Alzheimer's Association International Conference in Boston.

The gist is this: Their algorithm was able to gauge the likelihood of developing or not developing Alzheimer's within a range of 70% to 80% accuracy. That's significant because imaging and cerebrospinal fluid-based biomarkers generate similar results.

Lutz told the research gathering that they are encouraged enough that they'll be taking their biomarker risk assignment algorithm into a Phase III trial. The formula involves using age and APOE status in addition to the biomarker TOMM40 to predict the risk of mild cognitive impairment due to Alzheimer's within 5 years in older adults with normal cognition.

"Compared to only using APOE status and age as factors, the addition of TOMM40 makes this a promising biomarker risk assignment algorithm," Lutz said in a statement. "There is a tremendous need for tests to identify and predict the risk of mild cognitive impairment due to Alzheimer's disease."

The idea is that earlier diagnosis will enable sooner treatment, with the idea of slowing or stopping the progression of Alzheimer's before it creates too much cognitive damage. Takeda and Zinfandel inked their initial biomarker development deal back in January 2011.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->